Search

Your search keyword '"Tackenberg, Bjorn"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Tackenberg, Bjorn" Remove constraint Author: "Tackenberg, Bjorn"
31 results on '"Tackenberg, Bjorn"'

Search Results

1. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

2. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity

3. IL-17A secretion by [CD8.sup.+] T cells supports Th17-mediated autoimmune encephalomyelitis

4. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

5. Impaired inhibitory Fc[gamma]receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

6. Anti CD20 Therapies and Pregnancy in Neuroimmunological Disorders – A Case Series from Germany (P4.2-094)

10. Treatment choices and neuropsychological symptoms of a large cohort of early MS

11. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

12. 046 Efficacy and safety of intravenous immunoglobulin (IVIG) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP)

14. Efficacy and Safety of Intravenous Immunoglobulin (IVIG) IgPro10 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): the PRIMA and PATH studies (P1.153)

15. The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) patient cohort (P4.381)

16. 5 years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in Germany (P6.345)

17. 5 years safety of fingolimod in real world: First results from PANGAEA, a non-interventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice (P5.365)

18. 4 Years PANGAEA: A 5-Year Non-Interventional Study of Safety, Effectiveness and Pharmacoeconomic Data for Fingolimod Patients in Daily Clinical Practice - Effectiveness Update (P3.072)

19. TRUST - A Study to Evaluate an Integrated Approach for Optimized Patient Management in Multiple Sclerosis Patients Treated with Natalizumab - First Analysis of Baseline Data (P2.147)

21. Novel Multiple Sclerosis Genetic Risk Factors Are Involved in Epigenetic Regulation (S37.006)

22. Baseline Results of the Prospective Nationwide Cohort Study in Clinically Isolated Syndromes and Early Multiple Sclerosis of the German Competence Network Multiple Sclerosis and Monocentric Subgroup Analysis of Neuropsychological Findings (P1.392)

23. 4 Years Safety of Fingolimod in Real World: PANGAEA, a Non-Interventional Study of Safety, Effectiveness and Pharmacoeconomic Data for Fingolimod Patients in Daily Clinical Practice (P2.077)

29. Early Initiation of Fingolimod Treatment Reduces the Recurrence of Disease Activity after Natalizumab Discontinuation in Multiple Sclerosis (P01.199)

31. Cerebrospinal fluid concentrations of ghrelin in patients with multiple sclerosis.

Catalog

Books, media, physical & digital resources